Public Release:  A non-invasive method to track Huntington's disease progression

Journal of Clinical Investigation

Huntington's disease is a fatal, inherited neurodegenerative disorder caused by a mutation in the gene encoding huntingtin. Expresion of mutant huntingtin (mHTT) protein is correlated with the onset and progression of the disease and new therapies are being developed to reduce the expression of mHTT. In order to evaluate these new therapies, researchers need to be able to quantify the amount of mHTT in a particular patient; however, non-invasive quantification of mHTT isn't currently possible. In this issue of the Journal of Clinical Investigation, researchers led by Sarah Tabrizi at University College London report that mHTT can be detected in immune cells isolated during a normal blood draw. mHTT levels were significantly correlated with disease symptom severity, indicating that this test could serve as a non-invasive biomarker for Huntington's disease.

###

TITLE:

Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression

AUTHOR CONTACT:

Sarah Tabrizi

UCL Institute of Neurology, London, UNK, GBR

Phone: +44(0)2034484434; E-mail: s.tabrizi@prion.ucl.ac.uk

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.